- Single Book
155
- 10.1007/b138744
Pharmacokinetic-Pharmacodynamic Modeling and Simulation
- Jan 01, 2006
- Xh Huang + 1 more +1
Pharmacokinetic-Pharmacodynamic Modeling and Simulation
Longitudinal data are data collected repeatedly from each subject for a particular response variable over a certain time period. Specifically, in longitudinal data analysis, the researchers are interested in changes in the response levels over time and the differences in these changes among factor levels or covariates. Because of within-subject correlations, analysis methods considering the correlations or variance-covariance structures have been developed. One of the approaches is the use of mixed effects models that take into account between-subject heterogeneity by random effects. In population pharmacokinetics, the response variable corresponds to drug concentration and is analysed typically using nonlinear mixed effects models. In this article, longitudinal data analysis with a continuous response variable is introduced focusing on population pharmacokinetics. Longitudinal data analysis, linear mixed effects models, nonlinear mixed effects models, and population pharmacokinetics are discussed from a biostatistical point of view. This article is expected to be of interest to biostatisticians, pharmacologists, pharmacokineticists, and those in related fields.
Pharmacokinetic-Pharmacodynamic Modeling and Simulation
Pharmacokinetic-Pharmacodynamic Modeling and Simulation
Nonlinear Mixed Effects Models, Growth Curves, and Autoregressive Linear Mixed Effects Models
In the previous chapters, we discussed autoregressive linear mixed effects models. In this section, we discuss the relationships between the autoregressive linear mixed effects models and nonlinear mixed effects models, growth curves, and differential equations. The autoregressive model shows a profile approaching an asymptote, where the change is proportional to the distance remaining to the asymptote. Autoregressive models in discrete time correspond to monomolecular curves in continuous time. Autoregressive linear mixed effects models correspond to monomolecular curves with random effects in the baseline and asymptote, and special error terms. The autoregressive coefficient is a nonlinear parameter, but all random effects parameters in the model are linear. Therefore, autoregressive linear mixed effects models are nonlinear mixed effects models without nonlinear random effects and have a closed form of likelihood. When there are time-dependent covariates, autoregressive linear mixed effects models are represented by a differential equation and random effects. The monomolecular curve is one of the popular growth curves. We introduce other growth curves, such as the logistic curves and von Bertalanffy curves, and generalizations of growth curves. Re-parameterization is often performed in nonlinear models, and various representations of re-parameterization in monomolecular and other curves are provided herein.
Read moreEfficient hybrid EM for linear and nonlinear mixed effects models with censored response
Efficient hybrid EM for linear and nonlinear mixed effects models with censored response
Effect of correlation on covariate selection in linear and nonlinear mixed effect models.
The effect of correlation among covariates on covariate selection was examined with linear and nonlinear mixed effect models. Demographic covariates were extracted from the National Health and Nutrition Examination Survey III database. Concentration-time profiles were Monte Carlo simulated where only one covariate affected apparent oral clearance (CL/F). A series of univariate covariate population pharmacokinetic models was fit to the data and compared with the reduced model without covariate. The "best" covariate was identified using either the likelihood ratio test statistic or AIC. Weight and body surface area (calculated using Gehan and George equation, 1970) were highly correlated (r=0.98). Body surface area was often selected as a better covariate than weight, sometimes as high as 1 in 5 times, when weight was the covariate used in the data generating mechanism. In a second simulation, parent drug concentration and three metabolites were simulated from a thorough QT study and used as covariates in a series of univariate linear mixed effects models of ddQTc interval prolongation. The covariate with the largest significant LRT statistic was deemed the "best" predictor. When the metabolite was formation-rate limited and only parent concentrations affected ddQTc intervals the metabolite was chosen as a better predictor as often as 1 in 5 times depending on the slope of the relationship between parent concentrations and ddQTc intervals. A correlated covariate can be chosen as being a better predictor than another covariate in a linear or nonlinear population analysis by sheer correlation These results explain why for the same drug different covariates may be identified in different analyses. Copyright © 2016 John Wiley & Sons, Ltd.
Read moreComparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.
Different mixed-effects models were compared to evaluate the population dose-response and relative potency of two albuterol inhalers. Bronchodilator response was measured after ascending doses of each inhaler in 37 asthmatic patients. A linear mixed-effects model was developed based on the approach proposed by Finney for the evaluation of bioassay data. A nonlinear mixed-effects (Emax) model with interindividual and interoccasion variability (IOV) in the different pharmacodynamic parameters was also fit to the data. Both methods produced a similar estimate of relative potency. However, the estimate of relative potency was 22% lower with the nonlinear mixed-effects model if IOV was not taken into account. Monte Carlo simulations based on a similar study design demonstrated that more biased and variable estimates of ED50 and relative potency were obtained when the nonlinear mixed-effects model ignored the presence of IOV in the data. Furthermore, the linear mixed-effects model that did not account for IOV produced confidence intervals for relative potency that were too narrow and thus could lead to erroneous conclusions. These problems were avoided when the estimation model could account for IOV. Results of the simulations were consistent with those of the experimental data. Although the linear or the nonlinear mixed-effects model may be used to evaluate population dose-response and relative potency, there are important differences in the assumptions made by each method.
Read moreA sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models.
We propose a simple method to compute sample size for an arbitrary test hypothesis in population pharmacokinetics (PK) studies analysed with non-linear mixed effects models. Sample size procedures exist for linear mixed effects model, and have been recently extended by Rochon using the generalized estimating equation of Liang and Zeger. Thus, full model based inference in sample size computation has been possible. The method we propose extends the approach using a first-order linearization of the non-linear mixed effects model and use of the Wald chi(2) test statistic. The proposed method is general. It allows an arbitrary non-linear model as well as arbitrary distribution of random effects characterizing both inter- and intra-individual variability of the mixed effects model. To illustrate possible uses of the method we present tables of minimum sample sizes, in particular, with an illustration of the effect of sampling design on sample size. We demonstrate how (D-)optimal or frequent sampling requires fewer subjects in comparison to a sparse sampling design. We also present results from Monte Carlo simulations showing that the computed sample size can produce the desired power. The proposed method greatly reduces computing times compared with simulation-based methods of estimating sample sizes for population PK studies.
Read moreAn approximate method for generalized linear and nonlinear mixed effects models with a mechanistic nonlinear covariate measurement error model
The literature on measurement error for time-dependent covariates has mostly focused on empirical models, such as linear mixed effects models. Motivated by an AIDS study, we propose a joint modeling method in which a mechanistic nonlinear model is used to address the time-varying covariate measurement error for a longitudinal outcome that can be either discrete such as binary and count or continuous. We implement an inference procedure that uses first-order Taylor approximation to linearize both the covariate model and the response model. We study the asymptotic properties of the joint model based estimator and provide proof of consistency and normality. We then evaluate the performance of estimation in finite sample size scenario through simulation. Finally, we apply the new method to real data in an HIV/AIDS study.
Read moreModelling BMI Trajectories in Children for Genetic Association Studies
BackgroundThe timing of associations between common genetic variants and changes in growth patterns over childhood may provide insight into the development of obesity in later life. To address this question, it is important to define appropriate statistical models to allow for the detection of genetic effects influencing longitudinal childhood growth.Methods and ResultsChildren from The Western Australian Pregnancy Cohort (Raine; n = 1,506) Study were genotyped at 17 genetic loci shown to be associated with childhood obesity (FTO, MC4R, TMEM18, GNPDA2, KCTD15, NEGR1, BDNF, ETV5, SEC16B, LYPLAL1, TFAP2B, MTCH2, BCDIN3D, NRXN3, SH2B1, MRSA) and an obesity-risk-allele-score was calculated as the total number of ‘risk alleles’ possessed by each individual. To determine the statistical method that fits these data and has the ability to detect genetic differences in BMI growth profile, four methods were investigated: linear mixed effects model, linear mixed effects model with skew-t random errors, semi-parametric linear mixed models and a non-linear mixed effects model. Of the four methods, the semi-parametric linear mixed model method was the most efficient for modelling childhood growth to detect modest genetic effects in this cohort. Using this method, three of the 17 loci were significantly associated with BMI intercept or trajectory in females and four in males. Additionally, the obesity-risk-allele score was associated with increased average BMI (female: β = 0.0049, P = 0.0181; male: β = 0.0071, P = 0.0001) and rate of growth (female: β = 0.0012, P = 0.0006; male: β = 0.0008, P = 0.0068) throughout childhood.ConclusionsUsing statistical models appropriate to detect genetic variants, variations in adult obesity genes were associated with childhood growth. There were also differences between males and females. This study provides evidence of genetic effects that may identify individuals early in life that are more likely to rapidly increase their BMI through childhood, which provides some insight into the biology of childhood growth.
Read moreNon-linear mixed effects models for the evaluation of dissolution profiles
Non-linear mixed effects models for the evaluation of dissolution profiles
Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score.
Parallel designs with an end-of-treatment analysis are commonly used for randomised trials, but they remain challenging to conduct in rare diseases due to small sample size and heterogeneity. A more powerful alternative could be to use model-based approaches. We investigated the performance of longitudinal modelling to evaluate disease-modifying treatments in rare diseases using simulations. Our setting was based on a model describing the progression of the standard clinician-reported outcome SARA score in patients with ARCA (Autosomal Recessive Cerebellar Ataxia), a group of ultra-rare, genetically defined, neurodegenerative diseases. We performed a simulation study to evaluate the influence of trials settings on their ability to detect a treatment effect slowing disease progression, using a previously published non-linear mixed effect logistic model. We compared the power of parallel, crossover and delayed start designs, investigating several trial settings: trial duration (2 or 5years); disease progression rate (slower or faster); magnitude of residual error (σ=2 or σ=0.5); number of patients (100 or 40); method of statistical analysis (longitudinal analysis with non-linear or linear models; standard statistical analysis), and we investigated their influence on the type 1 error and corrected power of randomised trials. In all settings, using non-linear mixed effect models resulted in controlled type 1 error and higher power (88% for a parallel design) than a rich (75% for a parallel design) or sparse (49% for a parallel design) linear mixed effect model or standard statistical analysis (36% for a parallel design). Parallel and delayed start designs performed better than crossover designs. With slow disease progression and high residual error, longer durations are needed for power to be greater than 80%, 5years for slower progression and 2years for faster progression ataxias. In our settings, using non-linear mixed effect modelling allowed all three designs to have more power than a standard end-of-treatment analysis. Our analysis also showed that delayed start designs are promising as, in this context, they are as powerful as parallel designs, but with the advantage that all patients are treated within this design.
Read moreStochastic proximal-gradient algorithms for penalized mixed models
Motivated by penalized likelihood maximization in complex models, we study optimization problems where neither the function to optimize nor its gradient has an explicit expression, but its gradient can be approximated by a Monte Carlo technique. We propose a new algorithm based on a stochastic approximation of the proximal-gradient (PG) algorithm. This new algorithm, named stochastic approximation PG (SAPG) is the combination of a stochastic gradient descent step which—roughly speaking—computes a smoothed approximation of the gradient along the iterations, and a proximal step. The choice of the step size and of the Monte Carlo batch size for the stochastic gradient descent step in SAPG is discussed. Our convergence results cover the cases of biased and unbiased Monte Carlo approximations. While the convergence analysis of some classical Monte Carlo approximation of the gradient is already addressed in the literature (see Atchade et al. in J Mach Learn Res 18(10):1–33, 2017), the convergence analysis of SAPG is new. Practical implementation is discussed, and guidelines to tune the algorithm are given. The two algorithms are compared on a linear mixed effect model as a toy example. A more challenging application is proposed on nonlinear mixed effect models in high dimension with a pharmacokinetic data set including genomic covariates. To our best knowledge, our work provides the first convergence result of a numerical method designed to solve penalized maximum likelihood in a nonlinear mixed effect model.
Read moreSystemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting ?2-agonist, in different ethnic populations
To assess ethnic sensitivity of indacaterol systemic pharmacokinetics in Japanese vs. non-Japanese patients. Analyses were in three parts: data from a single "all Asian" clinical study; and two on pooled data - one using a linear mixed effects (LME) model and the other a non-linear mixed effects (NLME) model. The NLME model analyzed pharmacokinetic data from nine indacaterol studies; the LME model analyzed peak (C(max)) and trough (C(min)) serum concentration using data from four of these studies. In the all-Asian study, indacaterol serum concentration-time pharmacokinetic profiles in Japanese patients (n = 102) were similar to those in the overall population (n = 229). In the LME model, C(max) (4,392 observations, 1,845 patients) and C(min) (4,664 observations, 1,796 patients) for Japanese patients (n = 94) were on average 25% and 18% higher, respectively, than non-Japanese patients. However, after adjusting for study differences, this apparent ethnicity effect was not significant (p = 0.25 and 0.39, respectively). In the NLME model (25,540 observations, 2,857 patients), there was no statistically significant effect of Japanese (n = 230) ethnicity on indacaterol serum pharmacokinetics. No ethnicity effect was observed on indacaterol systemic pharmacokinetic profile for Japanese patients when compared with the overall Asian patient population or with the Caucasian patient population.
Read moreNonlinear Mixed Effects Models for Repeated Measures Data
We propose a general, nonlinear mixed effects model for repeated measures data and define estimators for its parameters. The proposed estimators are a natural combination of least squares estimators for nonlinear fixed effects models and maximum likelihood (or restricted maximum likelihood) estimators for linear mixed effects models. We implement Newton-Raphson estimation using previously developed computational methods for nonlinear fixed effects models and for linear mixed effects models. Two examples are presented and the connections between this work and recent work on generalized linear mixed effects models are discussed.
Read moreVarTestnlme: Variance Components Testing for Linear and Nonlinear Mixed Effects Models
An implementation of the Likelihood ratio Test (LRT) for testing that, in a (non)linear mixed effects model, the variances of a subset of the random effects are equal to zero. There is no restriction on the subset of variances that can be tested: for example, it is possible to test that all the variances are equal to zero. Note that the implemented test is asymptotic. This package should be used on model fits from packages 'nlme', 'lmer', and 'saemix'. Charlotte Baey and Estelle Kuhn (2019) <<a href="https://doi.org/10.18637%2Fjss.v107.i06" target="_top">doi:10.18637/jss.v107.i06</a>>.
Read morePopulation pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients
3567 Background: ABT-869 is an orally bioavailable, potent and specific inhibitor of all vascular endothelial growth factor and platelet derived growth factor family receptor tyrosine kinases. The objectives of this analysis were to understand the population pharmacokinetics of ABT-869 and explore the effect of several demographic/disease state covariates influencing ABT-869 disposition. Methods: A population PK analysis of 181 patients (pts) enrolled in two phase 1 (multiple types of solid tumors and AML) and three phase 2 monotherapy studies (non-small cell lung cancer, hepatocellular carcinoma [HCC] and renal cell carcinoma) was conducted. Approximately 90% of pts received ABT-869 based on body-weight dosing while the remaining pts had flat dosing. Available plasma concentrations obtained after intensive and sparse pre-dose PK sampling were analyzed by population PK using the non linear mixed effects modeling (NONMEM) approach. Potential covariates including body weight, body surface area (BSA), age, sex, creatinine clearance (CrCL) and disease state (HCC vs. non-HCC pts) were tested. Results: The mean body weight of enrolled pts was 71 kg and 57% were Asian, 36% Caucasian and 7% other races. The ABT-869 plasma concentration time profile was well described by a one-compartment model with first order absorption and elimination process. Oral clearance (CL/F) was not affected by body weight (range 35–177 kg); however, apparent volume of distribution (V/F) increased by 6L per 0.1 mg/m2 increase in BSA. CrCL (39.9–290.3 ml/min) was not a significant covariate on V/F and CL/F suggesting renally impaired pts do not require a different dose/dosing regimen. HCC pts had ∼40% lower CL/F values than pts with other malignancies suggesting a lower dose would be appropriate for HCC (Child Pugh A and B) pts. Conclusions: Population PK analysis showed that ABT-869 PK can be well described by a one-compartment model with first order absorption and elimination. Race and impaired renal function does not appear to alter PK. HCC pts had lower CL/F value therefore a lower dose may be recommended in these patients. Implications of increased V/F with increasing body size and appropriate dosing strategy are undergoing further analysis. [Table: see text]
Read more